Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study

医学 曲妥珠单抗 内科学 肿瘤科 养生 癌症 临床终点 临床试验 乳腺癌
作者
Qian Li,Huiqin Jiang,Hong Li,Rui‐Hua Xu,Lin Shen,Yiyi Yu,Yan Wang,Yuehong Cui,Wei Li,Shan Yu,Tianshu Liu
出处
期刊:Oncotarget [Impact Journals LLC]
卷期号:7 (31): 50656-50665 被引量:44
标识
DOI:10.18632/oncotarget.10456
摘要

// Qian Li 1, * , Huiqin Jiang 1, * , Hong Li 1, * , Ruihua Xu 2 , Lin Shen 3 , Yiyi Yu 1 , Yan Wang 1 , Yuehong Cui 1 , Wei Li 1 , Shan Yu 1 , Tianshu Liu 1 1 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China 2 Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China, Guangzhou, China 3 Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China * These authors have contributed equally to this work Correspondence to: Tianshu Liu, email: liu.tianshu@zs-hospital.sh.cn Keywords: advanced gastric cancer, HER2, trastuzumab, treatment beyond progression Received: March 18, 2016 Accepted: April 28, 2016 Published: July 07, 2016 ABSTRACT Introduction: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment. Methods: 59 patients were enrolled from Zhongshan Hospital Fudan University, Sun Yat-sen University Cancer Center and Peking University Cancer Hospital between September 2012 and Oct 2015. Patients were divided into two groups according to the second line regimens: with or without trastuzumab. The primary endpoint was progression free survival of second line therapy (PFS2). Secondary end points included overall survival (OS), response rate, and adverse events (AEs). Results: Baseline factors were well balanced between two groups. 32 patients treated with trastuzumab plus second line chemotherapy (group A) and 27 patients received chemotherapy alone (group B). The median follow-up time was 7.60 months (range 1.50-32.50). Longer median PFS2 was observed in group A than in group B (3.1 vs 2.0 months, P =0.008). There was no significant differences of median OS2 calculating from the second line therapy (10.5 vs 6.5 months, P =0.172) between two groups. Response rate was 9.3% in group A compared with 3.7% in group B ( P =0.617). AEs were similar in two groups including cardiac safety. Subgroup analysis showed that factors of male, age<65, good performance status, HER2 immunohistochemical (IHC) 2+ and poor response to first line indicated superior PFS2 in patients continuing trastuzumab to those treated with chemotherapy alone. Conclusion: Continuing treatment of trastuzumab beyond first line therapy progression showed effective and safe in AGC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
anna发布了新的文献求助10
1秒前
勤奋梨愁发布了新的文献求助10
2秒前
2秒前
潘善若发布了新的文献求助10
2秒前
momo发布了新的文献求助10
3秒前
3秒前
7秒前
9秒前
诺奇完成签到,获得积分10
11秒前
潘善若发布了新的文献求助10
13秒前
乖猫要努力应助猪猪hero采纳,获得10
13秒前
16秒前
16秒前
科目三应助不学无术采纳,获得10
16秒前
MrSong完成签到,获得积分10
20秒前
20秒前
momo发布了新的文献求助10
20秒前
小曾应助安静的万声采纳,获得10
21秒前
高贵的飞阳完成签到,获得积分10
21秒前
小梦发布了新的文献求助10
22秒前
22秒前
23秒前
科研通AI5应助GooJohn采纳,获得10
24秒前
Ava应助yyy采纳,获得10
28秒前
善学以致用应助yyy采纳,获得10
28秒前
共享精神应助yyy采纳,获得10
28秒前
李健的小迷弟应助yyy采纳,获得10
28秒前
JamesPei应助yyy采纳,获得10
28秒前
共享精神应助yyy采纳,获得10
28秒前
潘善若发布了新的文献求助10
28秒前
LL完成签到,获得积分10
29秒前
hu完成签到,获得积分10
31秒前
31秒前
32秒前
久久应助CSPC001采纳,获得10
33秒前
TaoBijiang完成签到,获得积分10
34秒前
34秒前
善学以致用应助勤奋梨愁采纳,获得10
35秒前
loststarts应助yyy采纳,获得10
35秒前
科研助手6应助yyy采纳,获得10
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136